Placebo News and Research

RSS

Study points to genetic/metabolic factors that make people vulnerable to nicotine addiction

In a study with 18 adults who had never smoked, scientists at Johns Hopkins report they have demonstrated one of the earliest steps — nicotine "reinforcement" — in the process of addiction, and shown that some people are far more vulnerable to nicotine addiction than others.

10 Sep 2015

National Association Of Science Writers Announces 2015 Science In Society Award Winners

Winners in each category receive a cash prize of $2,500, to be awarded at a reception on October 10, 2015, at the ScienceWriters2015 meeting taking place this year in Cambridge, Mass.

10 Sep 2015

Comprehensive review looks at safety, efficacy of treatment options for premenstrual dysphoric disorder

Premenstrual dysphoric disorder (PMDD) is a severe form of premenstrual syndrome that causes major disruption in several areas of life for many women. Many treatment options have been proposed, but which are most effective? A comprehensive review of the evidence, including specific treatment guidelines, is presented in the September Journal of Psychiatric Practice, published by Wolters Kluwer.

9 Sep 2015

Upfront combination therapy fulfils AMBITION in PAH patients

Upfront treatment with the combination of ambrisentan and tadalafil improves outcomes in patients with pulmonary arterial hypertension more than either treatment as monotherapy, shows a randomised trial.

9 Sep 2015

Botulinum toxin A improves muscle tone in hemiparesis

A single injection of abobotulinumtoxinA into upper limb muscles significantly reduces muscle tone in patients with hemiparesis following stroke or traumatic brain injury, study findings show.

9 Sep 2015

PAH treatments less effective in CTD-associated disease

Patients with connective tissue disease-associated pulmonary arterial hypertension have a poorer response to advanced PAH treatments than those with idiopathic disease, finds a meta-analysis.

9 Sep 2015

Riluzole ‘a candidate treatment’ for cerebellar ataxia

Riluzole may be an effective treatment for cerebellar ataxia, say researchers who call for further studies to confirm their findings.

9 Sep 2015

AcelRx's ARX-04 meets primary and secondary endpoints in Phase 3 trial

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that ARX-04 (sufentanil sublingual tablet, 30 mcg) met primary and secondary endpoints in a multi-center, double-blind, placebo-controlled Phase 3 trial (SAP301) designed to study the short-term treatment of patients with moderate-to-severe acute pain following ambulatory abdominal surgery.

9 Sep 2015

Egalet announces launch of OXAYDO (oxycodone HCI, USP) Tablets and IMPACT-Rx initiative

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing and commercializing innovative pain treatments, today announced the launch of OXAYDO (oxycodone HCI, USP) tablets -CII in the United States.

9 Sep 2015

Daily iron supplementation during pregnancy does not increase malaria risk in malaria-endemic region

Among women in a malaria-endemic region in Kenya, daily iron supplementation during pregnancy did not result in an increased risk of malaria, according to a study in the September 8 issue of JAMA. Iron supplementation did result in increased birth weight, gestational duration, neonatal length, and a decreased risk of low birth weight and prematurity.

9 Sep 2015

Helsinn, BIAL sign exclusive distribution and licence agreement for Anamorelin

Helsinn, the Swiss Group focused on building quality cancer care, and BIAL - Portela & Ca. S.A., one of the largest Iberian pharmaceutical companies, today announce that they have entered into an agreement for the exclusive distribution and licence rights to Anamorelin in Spain, Portugal, Angola and Mozambique.

8 Sep 2015

AstraZeneca presents lung cancer research data at WCLC 2015

Data will be reported from across AstraZeneca’s industry-leading lung cancer portfolio at the World Conference on Lung Cancer 2015, beginning this weekend in Denver, Colorado.

8 Sep 2015

Hutchison MediPharma achieves primary endpoint in POC Phase II study to treat NSCLC patients

Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited ("HMP"), its drug R&D subsidiary, successfully achieved the primary endpoint in the second proof-of-concept ("POC") trial of fruquintinib in patients with advanced non-squamous non-small cell lung cancer ("NSCLC") in China.

4 Sep 2015

Acupuncture may be viable treatment for women experiencing hot flashes

Acupuncture may be a viable treatment for women experiencing hot flashes as a result of estrogen-targeting therapies to treat breast cancer, according to a new study from researchers at the Perelman School of Medicine at the University of Pennsylvania. Hot flashes are particularly severe and frequent in breast cancer survivors, but current FDA-approved remedies for these unpleasant episodes, such as hormone replacement therapies are off-limits to breast cancer survivors because they include estrogen.

4 Sep 2015

Acupuncture: A viable treatment for breast cancer survivors experiencing hot flashes

3 Sep 2015

Scientists pinpoint neurons responsible for alcohol consumption

Scientists have pinpointed a population of neurons in the brain that influences whether one drink leads to two, which could ultimately lead to a cure for alcoholism and other addictions.

3 Sep 2015

Amgen announces MAA submission to EMA for novel calcimimetic agent etelcalcetide

Amgen today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency via the centralized procedure for etelcalcetide (formerly AMG 416) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis therapy. If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously.

3 Sep 2015

Mouse study shows active ingredient in marijuana may delay rejection of incompatible organs

Here's another discovery to bolster the case for medical marijuana: New research in mice suggests that THC, the active ingredient in marijuana, may delay the rejection of incompatible organs.

2 Sep 2015

Finerenone drug improves albuminuria among patients with diabetes and kidney disease

Among patients with diabetes and kidney disease, most receiving an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, the addition of the medication finerenone compared with placebo resulted in improvement in albuminuria (the presence of excessive protein [chiefly albumin] in the urine), according to a study in the September 1 issue of JAMA.

2 Sep 2015

Familial hypercholesterolemia patients can benefit from alirocumab drug

Alirocumab lowers cholesterol in patients with heterozygous familial hypercholesterolemia to levels unreachable with statins alone, according to results from four ODYSSEY trials presented at ESC Congress today.

2 Sep 2015

Placebo News and Research

Study points to genetic/metabolic factors that make people vulnerable to nicotine addiction

National Association Of Science Writers Announces 2015 Science In Society Award Winners

Comprehensive review looks at safety, efficacy of treatment options for premenstrual dysphoric disorder

Upfront combination therapy fulfils AMBITION in PAH patients

Botulinum toxin A improves muscle tone in hemiparesis

PAH treatments less effective in CTD-associated disease

Riluzole ‘a candidate treatment’ for cerebellar ataxia

AcelRx's ARX-04 meets primary and secondary endpoints in Phase 3 trial

Egalet announces launch of OXAYDO (oxycodone HCI, USP) Tablets and IMPACT-Rx initiative

Daily iron supplementation during pregnancy does not increase malaria risk in malaria-endemic region

Helsinn, BIAL sign exclusive distribution and licence agreement for Anamorelin

AstraZeneca presents lung cancer research data at WCLC 2015

Hutchison MediPharma achieves primary endpoint in POC Phase II study to treat NSCLC patients

Acupuncture may be viable treatment for women experiencing hot flashes

Acupuncture: A viable treatment for breast cancer survivors experiencing hot flashes

Scientists pinpoint neurons responsible for alcohol consumption

Amgen announces MAA submission to EMA for novel calcimimetic agent etelcalcetide

Mouse study shows active ingredient in marijuana may delay rejection of incompatible organs

Finerenone drug improves albuminuria among patients with diabetes and kidney disease

Familial hypercholesterolemia patients can benefit from alirocumab drug

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News